HUP0303662A2 - Laktámvegyületek és alkalmazásuk szerin proteázok inhibitoraiként és ezeket tartalmazó gyógyszerkészítmények - Google Patents

Laktámvegyületek és alkalmazásuk szerin proteázok inhibitoraiként és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0303662A2
HUP0303662A2 HU0303662A HUP0303662A HUP0303662A2 HU P0303662 A2 HUP0303662 A2 HU P0303662A2 HU 0303662 A HU0303662 A HU 0303662A HU P0303662 A HUP0303662 A HU P0303662A HU P0303662 A2 HUP0303662 A2 HU P0303662A2
Authority
HU
Hungary
Prior art keywords
alkyl
amino
carbonyl
cycloalkyl
aryl
Prior art date
Application number
HU0303662A
Other languages
English (en)
Inventor
Gregory S. Bisacchi
R. Michael Lawrence
Steven M. Seiler
William A. Slusarchyk
James C. Sutton
Guohua Zhao
Original Assignee
Bristol-Myers Squibb Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Co. filed Critical Bristol-Myers Squibb Co.
Publication of HUP0303662A2 publication Critical patent/HUP0303662A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08—Oxygen atoms
    • C07D223/10—Oxygen atoms attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

A találmány tárgyát az általános képletű vegyületek - ahol R1 és R2legalább egyike hidrogénatom, a másik pedig a hidrogénatom, alkil-,alkenil-, alkinil-, aril-, amino-alkil-aril-, amino-cikloalkil-aril-,amino-alkil-, amino-alkil-cikloalkil-, heteroaril-, aralkil-,heteroaralkil-, cikloalkil-, cikloalkil-alkil-, policikloalkil-,policikloalkil-alkil-, cikloalkenil-, cikloheteroalkil-, cikloalkenil-alkil-, policikloalkenil- vagy policikloalkenil-alkil-csoportok közülválasztható, amelyek mindegyike adott esetben 1, 2, 3 vagy 4szubsztituens csoportot hordozhat a hidrogén-, halogénatomok, alkil-,halogén-alkil-, alkoxi-, halogén-alkoxi-, alkenil-, alkinil-,cikloalkil-, cikloalkil-alkil-, cikloheteroalkil-, cikloheteroalkil-alkil-, aril-, heteroaril-, aralkil-, arilacikloalkil-, aralkenil-,aralkinil-, aril-oxi-, aril-oxi-alkil-, aralkoxi-, aril-azo-,heteroaralkil-, heteroaralkenil-, heteroaril-oxi-, hidroxi-, nitro-,ciano-, amino-, helyettesített amino-, alkil-amino-, dialkil-amino-,merkapto-, alkil-tio-, aril-tio-, heteroaril-tio-, aril-tioalkil-,amino-alkil-, alkil-oxi-karbonil-amino-alkil-, aralkil-oxi-karbonit-amino-alkil-, alkil-karbonil-, aril-karbonil-, aril-amino-karbonil-,amino-karbonil-, alkinil-amino-karbonil-, alkil-amino-karbonil-,alkenil-amino-karbonil-, alkil-karbonil-oxi-, aril-karbonil-oxi-,alkil-karbonil-amino-, aril-karbonil-amino-, aril-szulfinilaril-szulfinil-alkil-, arilszulfonil-, alkilszulfonil-, arilszulfonil-amino-, heteroaril-karbonil-amino-, heteroarilszulfinil-, heteroaril-tio-, heteroarilszulfonil- vagy alkilszulfinil-csoportok közül - Xjelentése R4-C- vagy R3-S<>- O2 Y általános képletű csoport, ahol Y-oxigén vagy kénatomot jelent. és gyógyszerészetileg elfogadható sóik,összes sztereoizomereik, és prodrug észtereik, és hipolipidémikusszerrel, b-adrenerg agonistával, antikolinergikummal,gyulladáscsökkentő kortikoszteroiddal vagy gyulladáscsökkentő szerrelképzett gyógyszerkombinációik, valamint szerin-proteázt inhibiálógyógyszerkészítmény előállítására történő alkalmazásuk képezik. Ó
HU0303662A 2000-08-07 2001-07-20 Laktámvegyületek és alkalmazásuk szerin proteázok inhibitoraiként és ezeket tartalmazó gyógyszerkészítmények HUP0303662A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/633,751 US6344450B1 (en) 1999-02-09 2000-08-07 Lactam compounds and their use as inhibitors of serine proteases and method
PCT/US2001/022829 WO2002012196A2 (en) 2000-08-07 2001-07-20 Lactam compounds and their use as inhibitors of serine proteases and method

Publications (1)

Publication Number Publication Date
HUP0303662A2 true HUP0303662A2 (hu) 2004-03-01

Family

ID=24540977

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0303662A HUP0303662A2 (hu) 2000-08-07 2001-07-20 Laktámvegyületek és alkalmazásuk szerin proteázok inhibitoraiként és ezeket tartalmazó gyógyszerkészítmények

Country Status (7)

Country Link
US (1) US6344450B1 (hu)
EP (1) EP1309609A2 (hu)
JP (1) JP2004521071A (hu)
AU (1) AU2001280642A1 (hu)
CA (1) CA2418995A1 (hu)
HU (1) HUP0303662A2 (hu)
WO (1) WO2002012196A2 (hu)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000026197A1 (en) * 1998-10-29 2000-05-11 Bristol-Myers Squibb Company Novel inhibitors of impdh enzyme
CN1678586A (zh) * 2002-06-27 2005-10-05 舍林股份公司 取代的喹啉ccr5受体拮抗剂
WO2004011019A1 (de) * 2002-07-25 2004-02-05 Charite-Universitäts Medizin Berlin Verwendung eines proteasom-inhibitors zur behandlung fibrotischer erkrankungen
DE10238002A1 (de) * 2002-08-20 2004-03-04 Merck Patent Gmbh Benzimidazolderivate
AU2002951912A0 (en) 2002-10-08 2002-10-24 Unisearch Limited Tryptase polypeptide and uses thereof
US20040180855A1 (en) * 2003-02-19 2004-09-16 Schumacher William A. Methods of treating thrombosis with reduced risk of increased bleeding times
PT1691814E (pt) * 2003-12-01 2012-10-16 Cambridge Entpr Ltd Agentes anti-inflamatórios
CN101090885A (zh) * 2004-02-23 2007-12-19 塔夫茨大学信托人 作为构象限定的肽模拟物抑制剂的内酰胺类化合物
SI1725234T1 (sl) 2004-03-05 2013-04-30 The Trustees Of The University Of Pennsylvania Postopki zdravljenja nepravilnosti ali bolezni povezanih s hiperlipidemijo in hiperholesterolemijo z minimiziranjem stranskih uäśinkov
US7361672B2 (en) 2004-12-23 2008-04-22 Hoffmann-La Roche Inc. Heteroarylacetamide inhibitors of factor Xa
EP1871741A4 (en) * 2005-04-04 2012-01-11 Daiamed Inc SUBSTITUTED AZETIDINONE
EP1951224A2 (en) * 2005-10-18 2008-08-06 Aegerion Pharmaceuticals Methods for treating disorders associated with hyperlipidemia in a mammal
US20080161279A1 (en) * 2006-12-21 2008-07-03 Wisler Gerald L Methods of Treating Obesity
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1247698B (it) 1990-06-21 1994-12-30 Sigma Tau Ind Farmaceuti 1-alchil-3-(acilammino)-e-caprolattami quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti
GB9200535D0 (en) 1992-01-10 1992-02-26 Fujisawa Pharmaceutical Co New compound
US5484917A (en) 1993-06-16 1996-01-16 Pfizer Inc. Substituted tetrahydrobenzazepinones
DK0711283T3 (da) 1993-07-26 1999-11-22 Pfizer Tetrahydro-1H-benzazepinoner og hexahydroazepinoner som selektive cholecystokinin-B-receptorantagonister
WO1995035311A1 (en) 1994-06-17 1995-12-28 Corvas International, Inc. 3-amino-2-oxo-1-piperidineacetic derivatives as enzyme inhibitors
US5703208A (en) 1994-06-17 1997-12-30 Corvas International, Inc. 3-amino-2-oxo-1-piperidineacetic derivatives as enzyme inhibitors
US5932733A (en) 1994-06-17 1999-08-03 Corvas International, Inc. 3-amino-2-oxo-1-piperidineacetic derivatives containing an arginine mimic as enzyme inhibitors
GB9420763D0 (en) 1994-10-14 1994-11-30 Glaxo Inc Acetamide derivatives
US5672598A (en) 1995-03-21 1997-09-30 The Procter & Gamble Company Lactam-containing hydroxamic acids
EP0761680A3 (en) 1995-09-12 1999-05-06 Ono Pharmaceutical Co., Ltd. Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity
AU713247B2 (en) 1995-10-19 1999-11-25 Merck & Co., Inc. Fibrinogen receptor antagonists
AU7604196A (en) 1995-10-30 1997-05-22 Merck & Co., Inc. Novel inhibitors of peptide binding to mhc class ii proteins
IL119466A (en) * 1995-11-03 2001-08-26 Akzo Nobel Nv Thrombin inhibitors, their preparation and pharmaceutical compositions containing them
WO1997030073A1 (en) 1996-02-13 1997-08-21 Akzo Nobel N.V. Serine protease inhibitors
IL120311A (en) * 1996-03-01 2001-10-31 Akzo Nobel Nv Serine protease inhibitors and pharmaceuticals containing them
JP3962091B2 (ja) 1996-09-19 2007-08-22 アベンティス・ファーマスーティカルズ・インコーポレイテッド マトリックスメタロプロテイナーゼの阻害剤として有用な３―メルカプトアセチルアミノ―１，５―置換―２―オキソーアゼパン誘導体
CA2268281A1 (en) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. Selective factor xa inhibitors
DK0979240T3 (da) * 1997-05-02 2004-07-26 Akzo Nobel Nv Serinproteaseinhibitor
FR2764511B1 (fr) 1997-06-13 2000-09-08 Sanofi Sa Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire
WO2000005208A1 (en) 1998-07-24 2000-02-03 Corvas International Inc. Amino-aldehyde solid support, linker therefor and methods of preparation and use thereof
CA2361919A1 (en) * 1999-02-09 2000-08-17 Bristol-Myers Squibb Company Lactam inhibitors of fxa and method
BR0010381A (pt) 1999-03-11 2002-02-05 Du Pont Pharm Co Método de tratamento da trombose em um mamìfero, e uso de uma combinação de (i) um inibidor do fator xa, e (ii) um composto selecionado do grupo que consiste em aspirina, tpa, um antagonista gpiib/iiia, heparina de baixo peso molecular e heparina
AU2001255408A1 (en) * 2000-04-14 2001-10-30 Corvas International, Inc. Tetrahydro-azepinone derivatives as thrombin inhibitors

Also Published As

Publication number Publication date
JP2004521071A (ja) 2004-07-15
US6344450B1 (en) 2002-02-05
AU2001280642A1 (en) 2002-02-18
EP1309609A2 (en) 2003-05-14
WO2002012196A3 (en) 2003-01-16
WO2002012196A2 (en) 2002-02-14
CA2418995A1 (en) 2002-02-14

Similar Documents

Publication Publication Date Title
HUP0303662A2 (hu) Laktámvegyületek és alkalmazásuk szerin proteázok inhibitoraiként és ezeket tartalmazó gyógyszerkészítmények
MA30952B1 (fr) Cyclopenta [d] pyrimidines utiles en tant qu&#39;inhibiteurs de la proteine kinase akt
HUP0303164A2 (hu) Kinazolinok mint MMP-13 gátlók, eljárás az előállításukra, intermedierjeik és a vegyületeket tartalmazó gyógyszerkészítmények
MY129796A (en) Novel anti-inflammatory androstane derivatives
AU2003297291A1 (en) Substituted arylcyclopropylacetamides as glucokinase activators
HUP0301120A2 (hu) Szubsztituált fenilamino-kinazolin-származékok, alkalmazásuk rendellenes sejtnövekedés kezelésére és azokat tartalmazó gyógyszerkészítmények
AU2008245082A8 (en) Aminodihydrothiazine derivatives substituted with a cyclic group
GEP20227359B (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
GEP20074124B (en) Azaindole kinase inhibitors
MX2008013583A (es) Compuestos del inhibidor de fosfoinositido 3-cinasa y composiciones farmaceuticas que los contienen.
MXPA04002167A (es) Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
HUP0104218A2 (hu) Új szubsztituált fenil-ciklohexil vegyületekből származó észterek
NO20092565L (no) Fosfoinositid 3-kinaseinhibitorforbmdelser og fremgangsmater for anvendelse
ES2170252T3 (es) Tetrahidroimidazopiridoindoldionas como inhibidores de cgmp especifico pde.
NO20055565L (no) Anvendelse av derivater av 2,4-dihydro-[1,2,4]triazol-3-thion som inhibitorer av enzymet myeloperoksidase (MPO)
HUP0301625A2 (hu) Réztartalmú amin-oxidáz inhibitor hatású 1,3,4-oxadiazin-vegyületek, eljárás az előállításukra és alkalmazásuk gyógyszerkészítmények előállítására
MA32343B1 (fr) Pyrimidyle cyclopentane hydroxylé en tant qu&#39;inhibiteur de protéine kinase akt
BR0313407A (pt) Novo uso de derivados de benzotiazol
MXPA05012247A (es) Derivados de bencimidazol nuevos.
AU2001230395A1 (en) Use of cox-2 inhibitors as gastroprokinetics
BRPI0721113A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para prevenir, tratar ou melhorar doenças ou condições dérmicas ou distúrbios
SE0302756D0 (sv) Novel Compounds
BR0307033A (pt) ácidos 3-(imidazolil)-2-aminopropanóicos para o uso como inibidores tafi-a para o tratamento de doenças trombóticas
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
TW200640870A (en) Novel compounds

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees